Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Neoplasms 6Prostatic Neoplasms 2Lymphoma, Follicular 2Lymphoma 2Leukemia, Lymphocytic, Chronic, B-Cell 2Small Cell Lung Carcinoma 1Neoplasm Metastasis 1Lymphoma, Mantle-Cell 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, B-Cell 1Locally Advanced Esophageal or GE Junction Cancer 1Hormone Refractory Prostate Cancer 1Disease 1Carcinoma, Non-Small-Cell Lung 1

Interventions

radium Ra 223 dichloride 2gossypol acetic acid 1bafetinib 1Mycobacterium w vaccine 1Docetaxel 1Denosumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Hormone Refractory Prostate Cancer × gossypol acetic acid × Clear all
NCT00286806 2010-08-24

A Study of Single-Agent AT-101 in Men With Hormone Refractory Prostate Cancer

Ascenta Therapeutics

Phase 1/2 Completed
27 enrolled
Genitourinary

Hormone Refractory Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡